Paxman is delighted to announce it has acquired Dignitana, another scalp cooling device manufacturer, and the two companies will merge to create a new, unified group named Paxman AB.
This landmark moment marks a pivotal point in the history of Paxman and Dignitana, beginning a new chapter in chemotherapy side effect management, full of opportunity. As two companies once working in competition, the merger will enable valuable collaboration and connections, the sharing of new perspectives, and leverage of each other’s strengths – all with the goal to improve patient outcomes.
Treating More Patients
At present, both Dignitana and Paxman treat less than 1% of the population who are eligible to receive and benefit from scalp cooling. Pooling resources, geographical spread, connections, and more, the new group will be able to offer a higher level of service, increase investment in new technologies, and fuel rapid growth into new areas of the world. It means more people will be able to benefit from our combined technologies and medical devices, particularly for the United States where the mechanised scalp cooling footprint will grow from 600 to 900 sites. Both Paxman and Dignitana are world leaders in scalp cooling technology and chemotherapy side effect management. The two companies share the same patient-centric values, both with the aim of making scalp cooling accessible to all those who want it. This includes any future chemotherapy side effect management technologies, such as Paxman’s limb cryocompression system, as we approach commercialisation in 2026.
About Dignitana
Dignitana is a Swedish medical technology company publicly traded on Nasdaq First North Growth Market. Its company headquarters are in Lund, Sweden with operations based in Dallas, Texas in the United States. The company develops, produces and markets The DigniCap® Scalp Cooling System for the prevention of chemotherapy-induced hair loss. For more information about Paxman, visit the About Page.
Next Steps for Paxman and Dignitana
“I am truly looking forward to collaborating, connecting, and combining the best of our two organisations, with new perspectives and shared strengths as we move forward.”
– Richard Paxman OBE, CEO of Paxman
It is important to note that for the moment, patients, healthcare practitioners, and other parties with links to either company will experience no change. Operations will continue as they have done previously until the new group, Paxman AB, performs its thorough review. In the long-term, any changes will be communicated clearly and in plenty of time to ensure that scalp cooling access continues smoothly for all. We are looking forward to the opportunities working together as one company brings, as we make an even bigger difference to patients facing the challenges of cancer and chemotherapy.